Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]
Current Sports Medicine Reports, 2017 Phosphodiesterase type 5 inhibitors (PDE5i) (e.g.,sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia. PDE5i are not prohibited by the World Anti-Doping Agency (WADA) but are alleged to be frequently misused by healthy athletes to ...
Di Luigi, Luigi +8 more
semanticscholar +7 more sources
Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes [PDF]
Membranes, 2021 Although phosphodiesterase type 5 inhibitors are widely used and well-studied drugs, the potential benefits of their application in the treatment of various diseases and new drug delivery systems, including liposome forms, are still being discussed.
Anastasiia A. Zakharova +2 more
doaj +2 more sources
COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Journal of Microscopy and Ultrastructure, 2020 COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension;
Al-Kuraishy, Hayder M. +5 more
openaire +4 more sources
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. [PDF]
Int J Endocrinol, 2020 Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency ...
Antinozzi C, Sgrò P, Di Luigi L.
europepmc +2 more sources
Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation. [PDF]
J Am Heart Assoc, 2020 Background Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure.
Xanthopoulos A +8 more
europepmc +2 more sources
UPLC-MS/MS-Based Target Screening of 90 Phosphodiesterase Type 5 Inhibitors in 5 Dietary Supplements [PDF]
MoleculesThe aim of individuals consuming health supplements is to attain a robust state through nutritional regulation. However, some unscrupulous manufacturers, motivated by profit, fraudulently incorporate drugs or unauthorized components with therapeutic ...
Shaoming Jin +6 more
doaj +2 more sources
A review of phosphodiesterase type 5 inhibitors [PDF]
South African Family Practice, 2014 Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction.
N. Schellack, A. Agoro
doaj +3 more sources
Phosphodiesterase type 5 Inhibitors (PDE-5I) as a potential therapeutic drug in stroke: A systematic narrative review [PDF]
Romanian Journal of Neurology, 2023 Objectives. Stroke is an acute cerebrovascular disease with high morbidity and mortality rate. Many stroke management strategies can improve prognosis and quality of life, but only to a certain extent.
Harvey Sudharta +5 more
doaj +2 more sources
EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil [PDF]
Sexual Medicine, 2017 Introduction Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s.
Giovanni Corona +2 more
openalex +2 more sources
Phosphodiesterase type 5 inhibitors and erectile dysfunction [PDF]
South African Family Practice, 2010 Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj +2 more sources